Clinical Trial Update: Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating pembrolizumab with IRX-2 and chemotherapy in triple-negative breast cancer; the study is active but not recruiting, with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• IRX-2
• Pembrolizumab (Keytruda) (pembrolizumab)

Snippet

Sponsor: Providence Health & Services | Conditions: Breast Cancer, Breast Neoplasms | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-12-02